2026 Q2 -tulosraportti
UUTTA
1 päivä sitten
‧28 min
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 6.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 21.8. | ||
2026 Q1 -tulosraportti 29.4. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 25.11.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
22 t sittenMid-Cycle and Late-Cycle Meetings Complete: Both major formal FDA review checkpoints have already occurred. The FDA confirmed it expects to complete its review by the September 28, 2026 PDUFA date without holding an Advisory Committee (AdCom) meeting……strong de risk in all aspects.
- ·23 t sittenAhaaaH! So I finally got into Egetis. Have waited long, but this financial report was approximately a perfect score! Emciitate sales up 23%, lots of cash and no hassle with FDA! Looking forward to the journey ahead. I imagine a 2x-3x bagger! We'll talk at price 10 on 28/9...
·9.8. · MuokattuThere's a lot written in here about price levels for Egetis for the period leading up to Sep. 28th, I myself am one of several writers. What I most recently wrote about price-action for Egetis actually unfolded - I suggested that the case just needed to retrace down into the area <6ish down to 5.80ish>. The case bottomed out at price 5.86. What happened was that Egetis hit an old top in the ongoing trading-range, showed weakness - after which it logically should retrace Fib50 to a level which was also medium-term support - and it played out exactly as assumed. Pure simple coincidence many might say - which is completely legitimate - no one can see into the future, not even yours truly! I took advantage of the now completed retrace to buy the case for my portfolio, and I'm not done buying - more shares are needed. In this context, I can also mention that in the trading system I had placed a stop-loss BUY order for activation at price 5.84 which naturally was NOT triggered, - as price-action bottomed out at price 5.86. That's how small margins can sometimes go against you :o) The next area that will be interesting to observe price-action in is just around the corner at price 7.4ish - here lie several old tops and bottoms - in the trading-range the case has now been in for the past approx. 6 years. Should price-action not have enough momentum, then a 'poke-up' in the price 7.4ish area will result in a new retrace down towards 6.6-6.4ish, before it probably seeks higher up again towards end-Sep. So right now I'm sitting on my hands and waiting for the price 7.4ish area to be hit. If price-action makes a break up through this area, 7.4<>7.6 - and immediately makes closing prices in / above this area - then momentum is strong and the case can be bought at current market price. If it shows weakness in this area, the case can be accumulated in a retrace that brings it down around price 6.6<>6.4ish again, before further ascent. Finally, a suggestion for the further price-action leading up to Sep. 28th. In my view, one should be prepared for profit-taking towards Sep. 28th, because in 99 out of 100 cases, that's what happens in price-action cases similar to this Egetis case. If the case just plays out somewhat bob-bob somewhat in the style of what I describe here - then there are still several 'low-hanging entries' to trade into the case leading up to Sep. 28th.@Heaton: It is still too early to talk about “price in USA” as the product is not yet approved in USA - this is the situation on which the whole case stands and wavers. Furthermore, as an investor, it is always a good idea to enter a case at ‘minimum risk’ which for this case is indicated to be in the area of price 7.40ish and lower - as this level represents the ceiling of the latest 6-year trading-range. Translated into plain language: Do not buy the case up to September 28th at price 8-10 kr (if these levels occur), as there will be selling days along the way until then. If Egetis misses its US NDA on September 28th, the case will move towards the bottom of the current trading-range - which will reduce the price level by approx. 50ish% There is a hell of a difference in your risk (25%) whether you have bought into the case at price 6.20-6.50ish or at price 8-10ish. Your statement “Everything else is noise, including different price levels” is in my opinion therefore neither correct, nor particularly nuanced. However, that does not mean that we both cannot make a profit on the case, and that is ultimately what it's all about - so good luck with that🙏
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q2 -tulosraportti
UUTTA
1 päivä sitten
‧28 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- 22 t sittenMid-Cycle and Late-Cycle Meetings Complete: Both major formal FDA review checkpoints have already occurred. The FDA confirmed it expects to complete its review by the September 28, 2026 PDUFA date without holding an Advisory Committee (AdCom) meeting……strong de risk in all aspects.
- ·23 t sittenAhaaaH! So I finally got into Egetis. Have waited long, but this financial report was approximately a perfect score! Emciitate sales up 23%, lots of cash and no hassle with FDA! Looking forward to the journey ahead. I imagine a 2x-3x bagger! We'll talk at price 10 on 28/9...
- ·9.8. · MuokattuThere's a lot written in here about price levels for Egetis for the period leading up to Sep. 28th, I myself am one of several writers. What I most recently wrote about price-action for Egetis actually unfolded - I suggested that the case just needed to retrace down into the area <6ish down to 5.80ish>. The case bottomed out at price 5.86. What happened was that Egetis hit an old top in the ongoing trading-range, showed weakness - after which it logically should retrace Fib50 to a level which was also medium-term support - and it played out exactly as assumed. Pure simple coincidence many might say - which is completely legitimate - no one can see into the future, not even yours truly! I took advantage of the now completed retrace to buy the case for my portfolio, and I'm not done buying - more shares are needed. In this context, I can also mention that in the trading system I had placed a stop-loss BUY order for activation at price 5.84 which naturally was NOT triggered, - as price-action bottomed out at price 5.86. That's how small margins can sometimes go against you :o) The next area that will be interesting to observe price-action in is just around the corner at price 7.4ish - here lie several old tops and bottoms - in the trading-range the case has now been in for the past approx. 6 years. Should price-action not have enough momentum, then a 'poke-up' in the price 7.4ish area will result in a new retrace down towards 6.6-6.4ish, before it probably seeks higher up again towards end-Sep. So right now I'm sitting on my hands and waiting for the price 7.4ish area to be hit. If price-action makes a break up through this area, 7.4<>7.6 - and immediately makes closing prices in / above this area - then momentum is strong and the case can be bought at current market price. If it shows weakness in this area, the case can be accumulated in a retrace that brings it down around price 6.6<>6.4ish again, before further ascent. Finally, a suggestion for the further price-action leading up to Sep. 28th. In my view, one should be prepared for profit-taking towards Sep. 28th, because in 99 out of 100 cases, that's what happens in price-action cases similar to this Egetis case. If the case just plays out somewhat bob-bob somewhat in the style of what I describe here - then there are still several 'low-hanging entries' to trade into the case leading up to Sep. 28th.@Heaton: It is still too early to talk about “price in USA” as the product is not yet approved in USA - this is the situation on which the whole case stands and wavers. Furthermore, as an investor, it is always a good idea to enter a case at ‘minimum risk’ which for this case is indicated to be in the area of price 7.40ish and lower - as this level represents the ceiling of the latest 6-year trading-range. Translated into plain language: Do not buy the case up to September 28th at price 8-10 kr (if these levels occur), as there will be selling days along the way until then. If Egetis misses its US NDA on September 28th, the case will move towards the bottom of the current trading-range - which will reduce the price level by approx. 50ish% There is a hell of a difference in your risk (25%) whether you have bought into the case at price 6.20-6.50ish or at price 8-10ish. Your statement “Everything else is noise, including different price levels” is in my opinion therefore neither correct, nor particularly nuanced. However, that does not mean that we both cannot make a profit on the case, and that is ultimately what it's all about - so good luck with that🙏
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 6.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 21.8. | ||
2026 Q1 -tulosraportti 29.4. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 25.11.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 |
2026 Q2 -tulosraportti
UUTTA
1 päivä sitten
‧28 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 6.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 21.8. | ||
2026 Q1 -tulosraportti 29.4. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 25.11.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- 22 t sittenMid-Cycle and Late-Cycle Meetings Complete: Both major formal FDA review checkpoints have already occurred. The FDA confirmed it expects to complete its review by the September 28, 2026 PDUFA date without holding an Advisory Committee (AdCom) meeting……strong de risk in all aspects.
- ·23 t sittenAhaaaH! So I finally got into Egetis. Have waited long, but this financial report was approximately a perfect score! Emciitate sales up 23%, lots of cash and no hassle with FDA! Looking forward to the journey ahead. I imagine a 2x-3x bagger! We'll talk at price 10 on 28/9...
- ·9.8. · MuokattuThere's a lot written in here about price levels for Egetis for the period leading up to Sep. 28th, I myself am one of several writers. What I most recently wrote about price-action for Egetis actually unfolded - I suggested that the case just needed to retrace down into the area <6ish down to 5.80ish>. The case bottomed out at price 5.86. What happened was that Egetis hit an old top in the ongoing trading-range, showed weakness - after which it logically should retrace Fib50 to a level which was also medium-term support - and it played out exactly as assumed. Pure simple coincidence many might say - which is completely legitimate - no one can see into the future, not even yours truly! I took advantage of the now completed retrace to buy the case for my portfolio, and I'm not done buying - more shares are needed. In this context, I can also mention that in the trading system I had placed a stop-loss BUY order for activation at price 5.84 which naturally was NOT triggered, - as price-action bottomed out at price 5.86. That's how small margins can sometimes go against you :o) The next area that will be interesting to observe price-action in is just around the corner at price 7.4ish - here lie several old tops and bottoms - in the trading-range the case has now been in for the past approx. 6 years. Should price-action not have enough momentum, then a 'poke-up' in the price 7.4ish area will result in a new retrace down towards 6.6-6.4ish, before it probably seeks higher up again towards end-Sep. So right now I'm sitting on my hands and waiting for the price 7.4ish area to be hit. If price-action makes a break up through this area, 7.4<>7.6 - and immediately makes closing prices in / above this area - then momentum is strong and the case can be bought at current market price. If it shows weakness in this area, the case can be accumulated in a retrace that brings it down around price 6.6<>6.4ish again, before further ascent. Finally, a suggestion for the further price-action leading up to Sep. 28th. In my view, one should be prepared for profit-taking towards Sep. 28th, because in 99 out of 100 cases, that's what happens in price-action cases similar to this Egetis case. If the case just plays out somewhat bob-bob somewhat in the style of what I describe here - then there are still several 'low-hanging entries' to trade into the case leading up to Sep. 28th.@Heaton: It is still too early to talk about “price in USA” as the product is not yet approved in USA - this is the situation on which the whole case stands and wavers. Furthermore, as an investor, it is always a good idea to enter a case at ‘minimum risk’ which for this case is indicated to be in the area of price 7.40ish and lower - as this level represents the ceiling of the latest 6-year trading-range. Translated into plain language: Do not buy the case up to September 28th at price 8-10 kr (if these levels occur), as there will be selling days along the way until then. If Egetis misses its US NDA on September 28th, the case will move towards the bottom of the current trading-range - which will reduce the price level by approx. 50ish% There is a hell of a difference in your risk (25%) whether you have bought into the case at price 6.20-6.50ish or at price 8-10ish. Your statement “Everything else is noise, including different price levels” is in my opinion therefore neither correct, nor particularly nuanced. However, that does not mean that we both cannot make a profit on the case, and that is ultimately what it's all about - so good luck with that🙏
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt